Drug Trial Radar · NCT07486817
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Aug 12, 2027
Study completion Aug 25, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with a type of lung cancer called HER2-mutant non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread. People who have a tumor with a HER2 mutation and have not received previous treatment for their lung cancer can participate in the study. The purpose of this study is to find out how well a medicine called zongertinib is tolerated in people with this type of lung cancer, when combined with chemotherapy, with or without pembrolizumab. Zongertinib works by targeting and blocking HER2, a protein involved in cancer cell growth. Participants are put into two groups randomly, which means by chance. One group gets zongertinib tablets combined with platinum-based chemotherapy. The other group gets the same treatment plus an additional medicine called pembrolizumab. Chemotherapy and pembrolizumab are given as an infusion into a vein. Participants take zongertinib by mouth once a day, while chemotherapy is given every 3 weeks for up to 3 months, followed by maintenance treatment for up to 2 years. Pembrolizumab is given every 3 weeks for up to 2 years. This study does not have a fixed duration. Participants can receive some of the study treatments for up to about 2 years and may continue to take zongertinib as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. Doctors regularly check the size of the tumor and whether it has spread. They also monitor participants' health and take note of any unwanted effects.
Conditions
- Lung Cancer, Non-squamous, Non-small Cell
Interventions
ZongertinibDrug
Zongertinib
CisplatinDrug
Cisplatin
CarboplatinDrug
Carboplatin
PemetrexedDrug
Pemetrexed
PembrolizumabDrug
Pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of discontinuation and/or prolonged interruption (>7 days) of zongertinib due to treatment-related adverse events (AEs) in the first 2 cycles of treatmentTime frame: up to 6 weeks
Locations
20 sites in 8 countries. Site status is shown where the registry gives one.
Royal North Shore Hospital
St Leonards, New South Wales, Australia · Not yet recruiting
Cabrini Health
Malvern, Victoria, Australia · Recruiting
Fiona Stanley Hospital
Murdoch, Western Australia, Australia · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, China · Recruiting
Shanghai Geriatric Medical Center
Shanghai, China · Recruiting
CTR Leon Berard
Lyon, France · Recruiting
INS Curie
Paris, France · Recruiting
Universitätsklinikum Köln (AöR)
Cologne, Germany · Recruiting
Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
Heidelberg, Germany · Recruiting
Kindai University Hospital
Osaka, Sakai, Japan · Recruiting
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
St James's University Hospital
Leeds, United Kingdom · Recruiting
The Royal Marsden Hospital, Chelsea
London, United Kingdom · Recruiting
The Royal Marsden Hospital, Sutton
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.